68 related articles for article (PubMed ID: 21358753)
1. Presence of tumoural C-reactive protein correlates with progressive prostate cancer.
Elsberger B; Lankston L; McMillan DC; Underwood MA; Edwards J
Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):122-8. PubMed ID: 21358753
[TBL] [Abstract][Full Text] [Related]
2. Expression of hypoxia inducible factor-1 alpha in matched hormone naive and castrate resistant prostate cancer specimens.
Elsberger B; Lankston L; Orange C; Underwood MA; Edwards J
Cancer Biomark; 2010-2011; 8(1):1-9. PubMed ID: 21896985
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
[TBL] [Abstract][Full Text] [Related]
4. Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer.
McCall P; Catlow J; McArdle PA; McMillan DC; Edwards J
Cancer Biomark; 2011-2012; 10(2):91-9. PubMed ID: 22430136
[TBL] [Abstract][Full Text] [Related]
5. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
Edwards J; Traynor P; Munro AF; Pirret CF; Dunne B; Bartlett JM
Clin Cancer Res; 2006 Jan; 12(1):123-30. PubMed ID: 16397033
[TBL] [Abstract][Full Text] [Related]
6. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
7. Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up.
McArdle PA; Qayyum T; McMillan DC
Urol Int; 2010; 84(4):430-5. PubMed ID: 20395655
[TBL] [Abstract][Full Text] [Related]
8. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
9. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer.
Koike Y; Miki C; Okugawa Y; Yokoe T; Toiyama Y; Tanaka K; Inoue Y; Kusunoki M
J Surg Oncol; 2008 Dec; 98(7):540-4. PubMed ID: 18937231
[TBL] [Abstract][Full Text] [Related]
10. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
11. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
[TBL] [Abstract][Full Text] [Related]
12. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer.
Castilla C; Congregado B; Conde JM; Medina R; Torrubia FJ; Japón MA; Sáez C
Urology; 2010 Oct; 76(4):1017.e1-6. PubMed ID: 20708221
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study.
Siemes C; Visser LE; Coebergh JW; Splinter TA; Witteman JC; Uitterlinden AG; Hofman A; Pols HA; Stricker BH
J Clin Oncol; 2006 Nov; 24(33):5216-22. PubMed ID: 17114654
[TBL] [Abstract][Full Text] [Related]
15. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma.
Shimada H; Nabeya Y; Okazumi S; Matsubara H; Shiratori T; Aoki T; Sugaya M; Miyazawa Y; Hayashi H; Miyazaki S; Ochiai T
J Surg Oncol; 2003 Aug; 83(4):248-52. PubMed ID: 12884238
[TBL] [Abstract][Full Text] [Related]
16. Bad expression influences time to androgen escape in prostate cancer.
Teo K; Gemmell L; Mukherjee R; Traynor P; Edwards J
BJU Int; 2007 Sep; 100(3):691-6. PubMed ID: 17542986
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease.
Wieland A; Kerbl R; Berghold A; Schwinger W; Mann G; Urban C
Med Pediatr Oncol; 2003 Jul; 41(1):21-5. PubMed ID: 12764738
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer.
Kato T; Suzuki H; Komiya A; Imamoto T; Naya Y; Tobe T; Ichikawa T
Int J Urol; 2006 Jul; 13(7):915-9. PubMed ID: 16882055
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
20. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers.
Krajewska M; Turner BC; Shabaik A; Krajewski S; Reed JC
Prostate; 2006 Jun; 66(8):801-10. PubMed ID: 16482527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
